ARMAGEN INC has a total of 32 patent applications. It increased the IP activity by 50.0%. Its first patent ever was published in 2010. It filed its patents most often in United States, EPO (European Patent Office) and Australia. Its main competitors in its focus markets biotechnology, pharmaceuticals and foods and drinks are VALERION THERAPEUTICS LLC, DIACCURATE and LIGACEPT LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 10 | |
#2 | EPO (European Patent Office) | 8 | |
#3 | Australia | 5 | |
#4 | Japan | 5 | |
#5 | WIPO (World Intellectual Property Organization) | 2 | |
#6 | Canada | 1 | |
#7 | Hungary | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Enzymes | |
#5 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Boado Ruben J | 25 |
#2 | Pardridge William M | 25 |
#3 | Ruben J Boado | 5 |
#4 | William M Pardridge | 5 |
#5 | Pardridge William | 2 |
#6 | Boado Ruben | 2 |
Publication | Filing date | Title |
---|---|---|
WO2020146359A1 | Methods and compositions for increasing galactosidase beta-1 activity in the cns | |
AU2019317460A1 | Methods and compositions for increasing the activity in the CNS of hexosaminidase a, acid sphingomyelinase, and palmitoyl-protein thioesterase 1 | |
US2016208006A1 | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU | |
EP3024848A1 | Methods and compositions for increasing enzyme activity in the cns | |
AU2011205186A1 | Fusion proteins for blood-brain barrier delivery | |
EP2408474A2 | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |